| P50 | author | Terence A Ketter | Q75471107 |
| P2093 | author name string | Antony Loebel | |
| | Josephine Cucchiaro | |
| | Robert Silva | |
| | Hans Kroger | |
| | Kaushik Sarma | |
| P2860 | cites work | Differentiating moderate and severe depression using the Montgomery-Asberg depression rating scale (MADRS). | Q51945770 |
| | A rating scale for extrapyramidal side effects | Q53780342 |
| | A 24-Week Open-Label Extension Study of Olanzapine-Fluoxetine Combination and Olanzapine Monotherapy in the Treatment of Bipolar Depression | Q57479549 |
| | Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure | Q72729639 |
| | A self-report questionnaire for measuring separation anxiety in adulthood | Q73176295 |
| | Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies | Q82208109 |
| | International Consensus Group on the evidence-based pharmacologic treatment of bipolar I and II depression | Q83294286 |
| | Young Mania Rating Scale: how to interpret the numbers? Determination of a severity threshold and of the minimal clinically significant difference in the EMBLEM cohort | Q86485574 |
| | Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study | Q86588500 |
| | Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication | Q22253024 |
| | A rating scale for drug-induced akathisia | Q28258433 |
| | The assessment of anxiety states by rating | Q29614719 |
| | A New Depression Scale Designed to be Sensitive to Change | Q29614720 |
| | A rating scale for mania: reliability, validity and sensitivity | Q29619299 |
| | Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). | Q34000973 |
| | Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study | Q34073723 |
| | Lamotrigine: a review of its use in bipolar disorder | Q34228876 |
| | The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults | Q34242471 |
| | Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression | Q34275783 |
| | Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators | Q34325168 |
| | Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis | Q34349641 |
| | A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression | Q34547560 |
| | The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression | Q34616633 |
| | Cardiovascular disease and hypertension among adults with bipolar I disorder in the United States | Q36108130 |
| | Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology | Q37426143 |
| | Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial | Q38489506 |
| | A comparison of depression rating scales | Q39240198 |
| | Maintenance treatment with quetiapine when combined with either lithium or divalproex in bipolar I disorder: analysis of two large randomized, placebo-controlled trials | Q42603284 |
| | A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. | Q42613693 |
| | Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. | Q44142664 |
| | Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study. | Q46037113 |
| | Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127). | Q46086886 |
| | Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression | Q46200033 |
| | The long-term natural history of the weekly symptomatic status of bipolar I disorder | Q46317822 |
| | Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). | Q46519540 |
| | A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression | Q46580881 |
| | Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies | Q46801835 |
| | Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study | Q48146535 |
| | Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study | Q48255293 |
| | Long-term efficacy of quetiapine in combination with lithium or divalproex on mixed symptoms in bipolar I disorder | Q48373114 |
| | Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study | Q48407645 |
| | Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome? | Q48657579 |
| | Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. | Q51900824 |
| P433 | issue | 5 | |
| P921 | main subject | bipolar disorder | Q131755 |
| P304 | page(s) | 424-434 | |
| P577 | publication date | 2016-02-26 | |
| P1433 | published in | Depression and Anxiety | Q15716773 |
| P1476 | title | LURASIDONE IN THE LONG-TERM TREATMENT OF PATIENTS WITH BIPOLAR DISORDER: A 24-WEEK OPEN-LABEL EXTENSION STUDY | |
| P478 | volume | 33 | |